Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Vilon

KE, L-Lys-L-Glu, lysylglutamic acid

Quick Stats
Studies 40
Trials 100
Recruiting OBSERVATIONAL NCT05321225

The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Detailed Description

Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB injury often occurs in the early stage of ischemic stroke, leading brain tissue edema or even hemorrhagic transformation with the development of ischemic injury. The biomarker of BBB damage, such as the level of serum occludin, can reflect the extent of BBB injury. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Interventions

Name: the level of biomarker in bood
Type: DIAGNOSTIC_TEST
Description: Elisa is used to test the level of biomarker in blood.

Primary Outcomes

Measure: The change of serum biomarkers within 72h in ischemic stroke patients
TimeFrame: Day 0, Day 1, Day 2, Day 3.
Description: The level of biomarkers are detected using Elisa(Enzyme Linked Immunosorbent Assay),biomarkers including Occludin(ng/mL), Claudin-5(ng/mL), MMP-2/9(ng/mL),c-Fn(ug/mL), ZO-1(pg/mL), vWF(ng/mL), IL-2RA(ng/mL), CCL16(ng/mL), CNTN(ng/mL), SELE(ng/mL) and PGLYRP1(ng/mL).

Trial Information

NCT ID

NCT05321225

Status

Recruiting

Study Type

OBSERVATIONAL

Sponsor

Ji Xunming,MD,PhD

Last Updated

December 15, 2025